First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers
“The transition of our first-of-its-kind GPR65 Inhibitor in immunooncology into the clinic represents a significant milestone for our company and is a validation of the promise of this approach and of the hard work of the entire Pathios team,” said Paul G. Higham, Chief Executive Officer of Pathios. “This multi-module trial has been carefully designed to provide a range of valuable data on PTT-4256 that will be critical to our continued clinical advancement of the program. In addition to important safety, tolerability and pharmacokinetic findings, this clinical trial includes investigating the activity of this novel target and mechanism in humans for the first time through measuring disease response and exploring links to biomarkers designed to elucidate the consequences of target engagement.”
Share:
More News
“CTT2274 has a unique structure and linker that maximizes tumor uptake and allows for release of the chemotherapeutic drug only within the tumor cell thus minimizing potential side effects from the chemotherapy. No other prodrug like this is being developed for prostate cancer and CTT2274 holds great promise as a
“HLX22-GC-301 is a double-blind, randomized, controlled multicenter phase 3 study aims to compare the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab as first-line treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced or metastatic
“We are encouraged by the consistent complete response rates observed in our expanded patient cohort,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “These results highlight the potential of ANKTIVA to transform the treatment landscape for patients with BCG-unresponsive NMIBC CIS, offering hope
“The collaborative End-of-Phase 2 meeting with the FDA represents another important milestone in our IMNN-001 clinical program, and we are very pleased that the Agency is aligned with the potential for IMNN-001 to address a significant unmet need in ovarian cancer treatment and our Phase 3 plans,” said Stacy Lindborg,
